CU Cancer Center

Research From CU Anschutz Cancer Center Member Chad Rusthoven, MD, Suggests New Paradigms for Preventing and Treating Brain Metastases in Small-Cell Lung Cancer

Written by Greg Glasgow | November 18, 2026

New research from University of Colorado Anschutz Cancer Center member and radiation oncologist Chad Rusthoven, MD, could change the way small-cell lung cancer patients are treated for current and future brain metastases.

PCI vs. MRI

Small-cell lung cancer has a higher rate of brain metastasis — or spread to the brain — than many other types of solid tumors, Rusthoven says, which in the 1970s and 1980s led to a therapy called prophylactic cranial irradiation (PCI) to prevent the metastases from happening.

“Investigators found that if you treated patients with PCI, or preventative brain radiation, that it reduced the rates of subsequent brain metastases significantly,” Rusthoven says. “Many of those patients had microscopic disease that was already in their brain, but it wasn't detectable with the available technology at the time, which was largely CT-based imaging.”

Because PCI can have harmful effects on cognitive function and quality of life, and because brain imaging has advanced with the advent of magnetic resonance imaging (MRI), Rusthoven wanted to see if MRI surveillance alone — and treating metastases if they arose — would yield similar results as MRI surveillance coupled with PCI. He launched a phase III clinical trial called SWOG S1827/MAVERICK in 2020 to examine the issue.

“We wanted to find out if close MRI surveillance alone would allow us to catch brain metastases early and offer more effective salvage therapy, while sparing patients the potential side effects of PCI,” he says. “The hypothesis was that MRI surveillance alone would result in better cognitive preservation and similar overall survival.”

The initial results of the MAVERICK trial were presented for the first time in September at the 2026 World Conference on Lung Cancer in Seoul, South Korea.

Promising results

With Rusthoven as principal investigator, the trial was open for six years at 139 institutions, mostly in the U.S. and Canada, but also in Mexico, South Korea, Chile, and Colombia.

The MAVERICK trial enrolled 304 patients. At a median follow up of 22 months among living patients, MRI surveillance alone significantly improved cognitive failure-free survival, the trial’s primary endpoint, reducing the risk of cognitive failure or death by 40% compared with MRI plus PCI. The benefit was similar among patients with limited-stage and extensive-stage disease and regardless of whether patients received immunotherapy.

“The trial demonstrated that MRI surveillance alone was associated with an improvement in the primary endpoint of cognitive-failure free survival. This means that patients treated with MRI alone were more likely to be both alive and free from cognitive decline than those treated with MRI surveillance plus PCI,” Rusthoven says. “Additionally, preliminary overall survival analyses suggested no significant differences between the arms.”

In the setting of rigorous standardized cognitive testing, MRI surveillance alone was associated with superior cognitive outcomes, including the domains of episodic learning, verbal fluency, processing speed, and executive function.

PCI was also associated with an increased risk of side effects, including hair loss, fatigue, headaches, and nausea.

Overall, the MAVERICK trial results support MRI surveillance alone without PCI as a management strategy for patients with small-cell lung cancer and no history of brain metastases. Rusthoven also noted that follow-up for overall survival remains ongoing and final results will be reported in the future.

When metastases occur

At the same time he was examining the benefit of MRI surveillance versus PCI, Rusthoven also served as the co-principal investigator, along with Vinai Gondi, MD, from Northwestern University, on a related trial called NRG CC009 — this one for small-cell lung cancer patients with brain metastases. In that study, the investigators were looking to see if stereotactic radiosurgery, a technique that delivers radiation directly to the brain metastasis, sparing exposure to the entire brain, had better results than whole-brain radiation — a low-dose radiation, similar to PCI, that’s delivered to the brain to treat metastases.

“In most settings, radiosurgery is preferred for patients who have limited brain metastases, but small-cell lung cancer is an exception where whole-brain radiation has remained the standard of care for one or more brain metastases,” Rusthoven says. “The reason for that was that doctors worried about how fast brain metastases could occur in small-cell lung cancer. There were concerns that if you only did focused treatments, then a few months later the patient might develop numerous brain metastases, resulting in worse outcomes.”

Knowing that whole-brain radiation has similar cognitive effects to PCI, Rusthoven and colleagues designed a trial to randomize patients with brain metastases to either stereotactic radiosurgery or a procedure called hippocampal avoidance whole-brain radiation, which is associated with better cognitive outcomes than standard whole brain radiation. Patients who received the latter treatment also received a drug called memantine, which is associated with better cognitive preservation.

Initial results were presented in September at the 2026 American Society for Radiation Oncology (ASTRO) annual meeting in Boston.

“We were evaluating whether radiosurgery would be associated with better cognitive preservation, because that's what we had seen in other histologies,” he says. “Interestingly, we found that the radiosurgery and the hippocampal avoidance whole brain radiation had very similar cognitive outcomes, but somewhat surprisingly, radiosurgery was associated with significantly better overall survival.”

Stereotactic radiosurgery, in fact, was associated with a near doubling in the median overall survival outcomes — from 8.6 months to 17.4 months.

“We did not see a difference in the primary endpoints of cognitive preservation, but the superior overall survival observed with radiosurgery addresses a fundamental historical objection to using radiosurgery alone for patients with small-cell lung cancer brain metastases, which was the concern that omission of whole-brain radiation could lead to worse outcomes in this population,” he says. “But what we observed in this randomized trial was the opposite result: that radiosurgery was associated with superior survival outcomes.”

Setting the stage for new treatment paradigms

Rusthoven and colleagues are now conducting research to better understand why radiosurgery survival outcomes were superior, but in the meantime, he is hoping the results of the two studies will start to change treatment options for small-cell lung cancer patients before and after they develop brain metastases.

“When we were developing these trials, there was basically a one-size-fits-all approach for preventing brain metastases, which was PCI, and for treating brain metastases, which was whole-brain radiation,” he says. “That made small-cell lung cancer an outlier, because in most other situations, including non-small cell lung cancer, we were increasingly individualizing treatment to try to achieve the best outcomes for our patients.

“Looking at the results of these two trials together, they suggest that we can start to individualize treatment for patients with small-cell lung cancer, as well,” he continues. “In the setting of close MRI surveillance, it's reasonable to omit PCI. And in the setting of brain metastases, it is reasonable to consider radiosurgery for appropriately selected patients. These results open the door to new multidisciplinary approaches for optimizing outcomes for patients with small cell lung cancer. I think that's a step in the right direction.”